1. Report Introduction 2. Attention-deficit/hyperactivity disorder (ADHD) Market Overview at a Glance 2.1. Market Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2016 2.2. Market Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2028 3. Disease Background and Overview: Attention-deficit/hyperactivity disorder (ADHD) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM 4.3. Total Prevalent Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM – By Countries 5. Epidemiology of Attention-deficit/hyperactivity disorder (ADHD) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.1.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.1.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.1.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.1.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.4.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.4.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.4.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.4.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.5.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.5.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.5.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.5.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.6.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.6.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.6.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.6.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.7.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.7.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.7.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.7.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.8.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.8.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.8.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.8.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.9.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.9.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) * 5.9.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) 5.9.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Attention-deficit/hyperactivity disorder (ADHD) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Attention-deficit/hyperactivity disorder (ADHD) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Attention-deficit/hyperactivity disorder (ADHD) : 7MM Market Analysis 12.1. 7MM Market Size of Attention-deficit/hyperactivity disorder (ADHD) 12.2. 7MM Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) 12.3. 7MM Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products 13. Attention-deficit/hyperactivity disorder (ADHD) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in United States 13.1.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in United States 13.1.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Germany 13.2.1.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Germany 13.2.1.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in France 13.2.2.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in France 13.2.2.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Italy 13.2.3.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Italy 13.2.3.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Spain 13.2.4.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Spain 13.2.4.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in United Kingdom 13.2.5.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Japan 13.3.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Japan 13.3.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM Table 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Table 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Table 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Table 7: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Table 11: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Table 12: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Table 14: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Table 15: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Table 16: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Table 17: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Table 21: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Table 22: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Table 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Table 27: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Table 30: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Table 31: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Table 32: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Table 36: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Table 37: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Table 42:7MM- Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Table 45: United States-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Table 48: Germany-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Table 51: France-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Table 54: Italy-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Table 57: Spain-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Table 60:UK-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Table 63: Japan-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM Figure 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Figure 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Figure 7: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Figure 12: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Figure 15: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Figure 16: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Figure 17: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Figure 22: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Figure 27: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Figure 31: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Figure 32: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Figure 37: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Figure 42:7MM- Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Figure 45: United States-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Figure 48: Germany-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Figure 51: France-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Figure 54: Italy-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Figure 57: Spain-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Figure 60:UK-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028) Figure 63: Japan-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)